Sign in Subscribe
Artificial intelligence

Artificial Intelligence in Clinical Trials Market to Reach $3.33 Billion by 2032

Strategic Insights

— 2 min read

The Artificial Intelligence (AI) in clinical trials market is expected to experience significant growth, driven by the increasing global burden of chronic diseases, significant investments in drug discovery and development, and technological advancements in software and services. The market is projected to reach $3.33 billion by 2032, reflecting a compound annual growth rate (CAGR) of 12.04 percent from 2025 to 2032.

Key Takeaways:

  • The AI in clinical trials market is expected to grow from $1.35 billion in 2024 to $3.33 billion by 2032, driven by the increasing global burden of chronic diseases and significant investments in drug discovery and development.
  • AI integration in clinical trials, particularly through software and services, has become crucial, with key technological advancements such as machine learning (ML) and natural language processing (NLP) playing a pivotal role in optimizing trial design, patient recruitment, and site monitoring.
  • The product segment of AI in clinical trials, particularly software, is set to hold a significant revenue share by 2024, with AI software allowing efficient patient matching and trial simulation.
  • North America is expected to dominate the AI in clinical trials market, driven by a rising prevalence of chronic diseases, significant R&D investments, and an increase in clinical trials.
  • Key market players such as TEMPUS, NetraMark, ConcertAI, AiCure, and Oracle are pivotal to the market landscape, with recent innovations like Suvoda's AI-powered assistant Sofia and Lokavant's SpectrumT driving operational efficiencies in trial management.
  • Despite promising growth prospects, challenges like patient data privacy and AI integration complexities remain, but the trend towards strategic partnerships and technological advancements continues to propel market growth.

Statistics:

  • The AI in clinical trials market is expected to reach $3.33 billion by 2032, reflecting a compound annual growth rate (CAGR) of 12.04 percent from 2025 to 2032.
  • The market is expected to grow from $1.35 billion in 2024 to $3.33 billion by 2032, driven by the increasing global burden of chronic diseases and significant investments in drug discovery and development.
  • There were 518,210 clinical trials reported globally by December 2024, up from prior years, necessitating effective AI tools for administration and data management.
  • The pharmaceutical R&D investments, such as the $276 billion in biopharmaceutical R&D noted by PhRMA in 2022, amplify the demand for AI-driven clinical trial solutions.
  • The AI in clinical trials market is expected to dominate the North American region, driven by a rising prevalence of chronic diseases, significant R&D investments, and an increase in clinical trials.

Sources:

  • ResearchAndMarkets.com's offering "Artificial Intelligence (AI) in Clinical Trials - Market Insights, Competitive Landscape, and Market Forecast - 2032"
  • PhRMA's report on pharmaceutical R&D investments in 2022
  • Recent data on clinical trials reported globally by December 2024

Read more